The second wave in kinase cancer drugs

Nature Biotechnology

Volumn 24, Issue 2, 2006, Pages 127-130

  Garber, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPHOSTIN; ANTINEOPLASTIC AGENT; AP 23846; ARRY 142886; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NILOTINIB; ONO 12380; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 880;

CANCER; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; NEOPLASMS; PHARMACOGENETICS; PROTEIN KINASE INHIBITORS; UNITED STATES;

EID: 32344438402     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0206-127     Document Type: Short Survey

References (9)

1. Daub H. et al. Nat. Rev. Drug Discov. 3, 1001-1010 (2004).
2. McInnes C. et al. Curr. Pharm. Des. 11, 1845-1863 (2005).
3. Branca, M. Nat. Biotechnol. 23, 639 (2005).
4. Manning G. et al. Science 298, 1912-1934 (2002).
5. Krause D.S. et al. New Engl. J. Med. 353, 172-187 (2005).
6. Lynch, T.J. et al. New Engl. J. Med. 350, 2129-2139 (2004).
7. Paez, J.G. et al., Science, 304, 1497-1500 (2004).
8. Neshat, M.S. et al., Proc Natl Acad Sci USA, 98: 10314-10319 (2001).
9. Podsypanina, K., et al., Proc Natl Acad Sci USA, 98: 10320-10325 (2001).